Pair Name	Wogonin, Cisplatin
Partner Name	Cisplatin
Disease Info	Head and neck cancer			/
Biological Phenomena	Induction-->ROS accumulation
Gene Regulation	Up-regulation	Expression	/	KEGG ID N.A.
	Up-regulation	Expression	BAX	hsa581
	Up-regulation	Phosphorylation	MAPK8	hsa5599
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Expression	NFE2L2	hsa4780
	Down-regulation	Expression	NQO1	hsa1728
	Up-regulation	Cleavage	PARP1	hsa142
In Vitro Model	HN4-cisR	Cisplatin-resistant human head and neck cancer	Homo sapiens (Human)	N.A.
	HN9-cisR	Cisplatin-resistant human head and neck cancer	Homo sapiens (Human)	N.A.
In Vivo Model	AMC-HN4-cisR or HN9-cisR cells (5×10⁶) were injected subcutaneously into the flank. Tumor volumes and body weights were measured every 3 days.
Result	Wogonin induced selective cell death by targeting the antioxidant defense mechanisms enhanced in the resistant HNC cells and activating cell death pathways involving PUMA and PARP. Hence, wogonin significantly sensitized resistant HNC cells to cisplatin both in vitro and in vivo. Wogonin is a promising anticancer candidate that induces ROS accumulation and selective cytotoxicity in HNC cells and can help to overcome cisplatin-resistance in this cancer.

Pair Name	Wogonin, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Down-regulation	Expression	NFE2L2	hsa4780
In Vitro Model	MCF-7(DOX/R)	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_C4M9
Result	Wogonin reversed drug resistance and its reversal mechanism might be due to the suppression of Nrf2 signaling pathway, indicating the feasibility of using Nrf2 inhibitors to increase efficacy of chemotherapeutic drugs.